Riskpilot← Back to searchSign inGet full accessTäsmälääke Oy
OYDissolvedY-tunnus 3161551-8Alatie 15Computer programming activities · NACE 6210Est. 2020— employees
Revenue 2025
EUR 0
EBITDA margin
—
-95% vs 2023
Equity ratio
90.6%
Financial strength
Net profit 2025
EUR 394
+109% vs 2023
| Revenue | EUR 0 | — |
| EBITDA | EUR 858 | -95% |
| Net profit | EUR 394 | +109% |
| Total assets | EUR 1K | -29% |
| Equity | EUR 940 | +72% |
| Employees | — | — |
Legal name
Täsmälääke Oy
Y-tunnus number
3161551-8
Legal form
Osakeyhtiö
NACE code
6210 · Computer programming activities
Founded
30. syyskuuta 2020
Share capital
EUR 0
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Hallituksen jäsenet ja toimitusjohtaja kukin yksin
Company purpose
Yhtiön toimiala on tarjota tietotekniikka-alan asiantuntijapalveluita sisältäen muun muassa konsultointi-, ohjelmistokehitys- ja koulutuspalvelut sekä muut niihin liittyvät palvelut. Lisäksi yhtiö voi harjoittaa yleistä liikkeenjohdon konsultointia sekä tapahtumien järjestämistä. Yhtiö voi omistaa, ostaa, myydä, hallita ja vuokrata huoneistoja, kiinteistöjä, arvopapereita, osakkeita, osuuksia ja oikeuksia kotimaassa ja ulkomailla sekä harjoittaa sijoitustoimintaa.
Address
Alatie 15
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|
| Revenue | 209 | 145 | 2 | 0 |
| Staff expenses | −79 | 87 | 4 | — |
| EBITDA | 111 | 276 | 18 | 1 |
| Depreciation & amort. | −7 | 5 | — | — |
| EBIT | 104 | 8 | −4 | 0 |
| Net financials | −1 | −2 | −0 | — |
| Profit before tax | 104 | 7 | −5 | 0 |
| Tax | 21 | 2 | −0 | 0 |
| Net profit | 83 | 5 | −5 | 0 |
| Item | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|
| Total assets | 140 | 46 | 1 | 1 |
| Equity | 83 | 5 | 1 | 1 |
| Long-term debt | 22 | 10 | 0 | — |
| Short-term debt | 35 | 32 | 1 | 0 |
| Total debt | 57 | 41 | 1 | 0 |
EBITDA margin
85800.0%
This company
15.8%
Market median
+542938% vs market
20212025
Equity ratio
90.6%
This company
38.2%
Market median
+137% vs market
20212025
Return on equity
41.9%
This company
18.4%
Market median
+128% vs market
20212025
Net profit margin
39400.0%
This company
8.1%
Market median
+486320% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2024-01-01 – 2025-06-30
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2020-09-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MJ Deputy Member | Deputy Member | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Täsmälääke Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mari Johanna Korhonen | Deputy Member | 0 companies |
| Juha Henrik Korhonen | Board of Directors | 0 companies |